The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial

BACKGROUND: Ivermectin inhibits the replication of SARS-CoV-2 in vitro at concentrations not readily achievable with currently approved doses. There is limited evidence to support its clinical use in COVID-19 patients. We conducted a Pilot, randomized, double-blind, placebo-controlled trial to evalu...

Full description

Saved in:
Bibliographic Details
Published in:EClinicalMedicine
Main Authors: Chaccour, Carlos, Casellas, Aina, Blanco-Di Matteo, Andrés, Pineda, Iñigo, Fernandez-Montero, Alejandro, Ruiz-Castillo, Paula, Richardson, Mary-Ann, Rodríguez-Mateos, Mariano, Jordán-Iborra, Carlota, Brew, Joe, Carmona-Torre, Francisco, Giráldez, Miriam, Laso, Ester, Gabaldón-Figueira, Juan C., Dobaño, Carlota, Moncunill, Gemma, Yuste, José R., Del Pozo, Jose L., Rabinovich, N.Regina, Schöning, Verena, Hammann, Felix, Reina, Gabriel, Sadaba, Belen, Fernández-Alonso, Mirian
Format: Artigo
Language:Inglês
Published: Elsevier 2021
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7816625/
https://ncbi.nlm.nih.gov/pubmed/33495752
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2020.100720
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items